Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2024-02-15 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Launches Ganirelix Acetate Injection in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Ganirelix Acetate Injection) following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a corporate announcement about a product launch and regulatory approval, not a financial report or earnings release. The document length is 4163 characters, which is relatively short and typical for a press release or regulatory announcement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-15 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Ganirelix Acetate Injection) in the United States after FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion of financial results. It is a corporate announcement about a product launch and regulatory approval, not a financial report or earnings release. The document length is 4153 characters, which is relatively short and consistent with a press release or regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q3 FY2024 earnings conference call for Lupin Limited, dated February 8, 2024. It includes management commentary on financial performance, segment results, R&D updates, and a Q&A session with analysts. The text explicitly states it is a transcript of the earnings call, which is a full text record of the conference call including Q&A. This matches the definition of a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive financial data and management discussion, confirming it is not merely an announcement or summary. Therefore, the correct classification is Call Transcript (CT).
2024-02-14 English
Transcript of Q3 FY2024 Earnings Conference Call.
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q3 FY2024 earnings conference call for Lupin Limited. It includes management commentary on financial performance, business segments, R&D updates, and a Q&A session with analysts. The presence of a full transcript of the earnings call, including management remarks and Q&A, clearly identifies this as a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive discussion of quarterly financial results, consistent with an earnings call transcript rather than a brief earnings release or announcement.
2024-02-14 English
Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in the United States.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bromfenac Ophthalmic Solution) in the United States following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or comprehensive report data. It is a corporate announcement about a product launch and regulatory approval, not a financial report or earnings release. The length is 4035 characters, which is relatively short and typical for a press release. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it relates to a significant business development impacting the company's operations and potentially its market value.
2024-02-13 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Bromfenac Ophthalmic Solution) in the United States following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, indicating it is a regulatory announcement. The document is short (4044 characters) and primarily serves as an announcement of a business event rather than a detailed financial report or earnings release. There are no financial statements, earnings highlights, or detailed management discussion. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is a regulatory announcement about a product launch and FDA approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under listing obligations.
2024-02-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.